Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 5, 2015, Pages 508-514

  Giri, Smith ^a   Hamdeh, Shadi ^b   Bhatt, Vijaya Raj ^c   Schwarz, James K ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZACITIDINE; CD135 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD71 ANTIGEN; CYTARABINE; DAUNORUBICIN; ELECTROLYTE; ENOXAPARIN; FILGRASTIM; GLUCOSE; HEMOGLOBIN; HYDROXYUREA; IDARUBICIN; MYELOPEROXIDASE; NUCLEOPHOSMIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ANOREXIA; ARTICLE; ATRIAL FIBRILLATION; BARRETT ESOPHAGUS; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CASE REPORT; CELL GRANULE; CHILL; CLOSTRIDIUM DIFFICILE INFECTION; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CONTROL; DYSPEPSIA; EMERGENCY WARD; FAMILY HISTORY; FEBRILE NEUTROPENIA; FEVER; GASTROESOPHAGEAL REFLUX; GENE AMPLIFICATION; GENE MUTATION; GLAUCOMA; GLEASON SCORE; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERNAL TANDEM DUPLICATION MUTATION; KARYOTYPE 46,XY; KIDNEY FUNCTION TEST; LABORATORY TEST; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PROSTATE ADENOCARCINOMA; RASH; RECTUM HEMORRHAGE; SEPSIS; THORAX PAIN; THROMBOCYTE COUNT; WEAKNESS; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; GENE DUPLICATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION; RECURRENT DISEASE; TANDEM REPEAT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RECURRENCE; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 84984551804     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0070     Document Type: Article

References (30)

1. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-3734.
2. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88:318-327.
3. Metzelder SK, Wollmer E, Neubauer A,rchert A. Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option [in German]. Dtsch Med Wochenschr 2010;135:1852-1856.
4. Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials 2007;2:135-141.
5. Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 2010;8:429-436, 444.
6. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-6571.
7. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-198.
8. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-1862.
9. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176-2185.
10. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-1759.
11. Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013;121:2734-2738.
12. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993.
13. Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multitargeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-4345.
14. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-3270.
15. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-3676.
16. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
17. Weisberg E, Barrett R, Liu Q, et al. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009;12:81-89.
18. Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014;123:94-100.
19. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3,-PDGFRA and-KIT isoforms. Mol Cancer 2013;12:19.
20. Zhang W, Gao C, Konopleva M, et al. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res 2014 2014;20:2363-2374.
21. Zirm E, Spies-Weisshart B, Heidel F, et al. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 2012;157:483-492.
22. Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121:3165-3171.
23. Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010;24:1437-1444.
24. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96:62-68.
25. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/ refractory leukemia. J Clin Oncol 2011;29:3293-3300.
26. Macdonald DA, Assouline SE, Brandwein J, et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk lymphoma 2013;54:760-766.
27. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121:4655-4662.
28. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31:3110-3118.
29. Sammons SL, Pratz KW, Smith BD, et al. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol 2014;89:936-938.
30. O'Donnell MR, Tallman MS, Abboud CN, et al. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 1.2015. Available at: NCCN.org. Accessed April 17, 2015.